Lenacapavir Sodium

Records for this ingredient, by country (identity only).

ATC J05AX31 · 3 markets · 9 records

Lenacapavir Sodium 3 markets · 9 records Forms
Filters
MarketAU 5SG 2FR 2

AU 5 records · 2 shown of 2 Source TGA · Data as of 2026-10-28 · includes records with unknown status (not proof of sale)

  • 306.8 mgtabletSUNLENCA lenacapavir (as sodium) 300 mg film coated tablet blister packSUNLENCA lenacapavir (as sodium) 300 mg film coated tablet bottle、YEYTUO lenacapavir (as sodium) 300 mg tablet bottle unknown
  • 473.1 mg per mL / per unit basis not statedinjectionSUNLENCA lenacapavir (as sodium) 463.5 mg/1.5 mL solution for injection vialYEYTUO lenacapavir (as sodium) 463.5 mg/1.5 mL solution for injection vial unknown

SG 2 records · 2 shown of 2 Source Health Sciences Authority (HSA) · Data as of 2026-08-07

FR 2 records · 2 shown of 2 Source Base de données publique des médic · Data as of 2026-11-03

  • 300 mgtabletSUNLENCA 300 mg, comprimé pelliculé also in SG
  • 464 mg per mL / per unit basis not statedinjectionSUNLENCA 464 mg, solution injectable

Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.